News
Libtayo filed in Japan to treat patients with cervical cancer.
Sanofi has filed a new drug application for its PD-1 inhibitor cemiplimab (Libtayo) in Japan on March 18 as a monotherapy for the treatment of patients with cervical cancer whose disease progressed on or after chemotherapy.
The submission is based on data from a global PIII study, which enrolled roughly 600 patients with relapsed/metastatic cervical cancer previously treated with chemotherapy. In the study, cemiplimab demonstrated a 31% reduction in the risk of deaths versus chemotherapy.
Condition: Cervical Cancer
Type: drug
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.